The prevalence of lung cancer in idiopathic pulmonary fibrosis (IPF) patients ranges from 9.8 to 38%. Nintedanib, a small molecule receptor tyrosine kinase inhibitor (TKI) of platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR), has been approved for IPF after phase III INPULSIS trials in 2014. Ramucirumab, a monoclonal antibody for VEGFR-2, combined with docetaxcel, has been approved for advanced nonsmall cell lung cancer (NSCLC) after the phase III REVEL trail in 2014. Physicians will have more IPF patients being treated with nintedanib, who subsequently develop NSCLC, and therefore will likely be treated with ramucirumab plus docetaxel. We report the first case of 70-year-old man taking nintedanib for his IPF and treated with ramucirumab plus docetaxel as a seventh-line therapy for his pulmonary adenocarcinoma. On day 15 of his chemotherapy treatment cycle 2, after taking nintedanib for nine days, he developed gastric perforation.
Introduction
Nintedanib, a small molecule receptor tyrosine kinase inhibitor (TKI) of platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR), was approved as a treatment for idiopathic pulmonary fibrosis (IPF) in 2014. Ramucirumab, a monoclonal antibody against VEGFR-2, combined with docetaxcel, has also been recently approved as a second-line chemotherapy for advanced non-small cell lung cancer (NSCLC). The prevalence of lung cancer in IPF patients is reported to range from 9.8 to 38% [1] . The number of patients taking nintedanib for their IPF who develop lung cancer, with the probability of being treated with ramucirumab plus docetaxel, will likely increase. We report the first case of gastric perforation related to the concurrent use of nintedanib for IPF and ramucirumab for NSCLC.
Case Report
A 70-year-old man with a smoking history of 47 packyears was diagnosed with epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK), or c-ros oncogene 1 (ROS1) fusion genes negative stage IIIB (T1aN3M0) pulmonary adenocarcinoma in July 2015. He had chronic renal failure and combined pulmonary fibrosis and emphysema. He was treated with several lines of cytotoxic agents and nivolumab. Interstitial pneumonia progressed in January 2018 and was treated with prednisolone until May 2018. As his tumour started to progress rapidly, ramucirumab plus docetaxel were initiated as a seventhline therapy in May 2018 and showed a favourable response. As his pulmonary fibrosis also started to progress, 200 mg/day of nintedanib was started on day 3 of the chemotherapy treatment cycle 2. He had fever and appetite loss from cycle2 day9 (C2D9) and made an unscheduled visit on C2D11. He was febrile with a body temperature of 37. 
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Respirology Case Reports meropenem every 8 hours (q8h) was stared. On day 2, his anaemia worsened (Hb 6.6 g/dL). As meropenem was not effective, 30 mg/day prednisolone was started on day 4, and the patient responded. He developed epigastric pain on day 5, and free air under the diaphragm was noted on a chest Xray and CT scan the next day (Fig. 1A,B) . Prednisolone was discontinued, and emergency surgery consisting of reefing of gastric perforation and coating with greater omentum was performed. A round perforation, 7 × 9 mm, was found on the posterior wall of the antrum of the lesser curvature of the stomach ( Fig. 2A) . His postoperative recovery was unremarkable. He started to eat on postoperative day 3. His pulmonary fibrosis was aggravated, and 30 mg/day of prednisolone was resumed on postoperative day 5. Prednisolone was continued, and his pulmonary fibrosis improved while chemotherapy was discontinued, and his lung cancer progressed. Follow-up gastroscopy performed on postoperative day 25 showed a well-healed scar without any carcinoma (Fig. 2B) . He was discharged from our hospital on postoperative day 28.
Discussion
Ramucirumab is a monoclonal antibody against VEGFR-2. Ramucirumab plus docetaxel has been approved as second-line chemotherapy for advanced NSCLC. Gastrointestinal perforation has been reported in 0.8% patients treated with ramucirumab monotherapy and in 1.5% of patients treated with ramucirumab plus docetaxel [2] . Nintedanib is a small molecule receptor TKI of PDGFR α and β, FGFR1-3, and VEGFR1-3. Pirfenidone and nintedanib are currently the only therapies approved for IPF [3] . Diarrhoea and liver dysfunction are the frequently reported adverse effects of nintedanib. Gastrointestinal perforation is rare and reported to occur in 0.2% of patients [4, 5] . Nintedanib plus docetaxel was shown to be safe and effective for patients with advanced NSCLC previously treated with platinum-based therapy by phase III trials and has been approved by the European Medicines Agency as a second-line treatment. In addition, a randomized study of carboplatin plus nanoparticle albumin-bound paclitaxel with or without nintedanib for patients with advanced NSCLC and concurrent IPF is currently running in Japan. Nintedanib can suppress progression of both NSCLC and IPF and is probably safe to be used in combination with certain kinds of cytotoxic anticancer drugs.
On the other hand, in phase II trials for several types of cancer, such as breast or renal cell carcinoma, combination therapy consisting of bevacizumab, a monoclonal antibody for VEGF, and multi-targeted TKI, such as sorafenib, pazopanib, or telatinib blocking VEGF signalling pathway, showed substantial toxicity and minimal efficacy, leading to these phase II trials being aborted.
The underlying mechanism of gastrointestinal perforation during antiangiogenic treatment is probably regression of normal blood vessels by excessive VEFG inhibition, although the exact mechanism still remains unclear. Therefore, concurrent use of ramucirumab and nintedanib in our case probably increased gastrointestinal perforation risk by inhibiting VEGF signal more strongly than monotherapy with ramucirumab or nintedanib. Previous long-term prednisolone use might have also contributed to the gastric perforation.
Previous reported cases show that the major risk factors for gastrointestinal perforation associated with antiangiogenic treatment are three or more prior chemotherapy regimens, primary tumour site, recent history of endoscopy or abdominal radiotherapy, and abdominal surgery [6] . In our case, there was no carcinoma at the site of perforation, but ramucirumab plus docetaxel was the seventh line of treatment. Most gastrointestinal perforations occurred within the first 3 months of ramcirumab treatment. Similar to those reports, gastric perforation in our patient occurred one month after initiating ramcirumab.
In summary, the prevalence of lung cancer in IPF patients ranges from 9.8 to 38% [1] . The number of patients taking nintedanib for their IPF, and who may be prescribed ramucirumab plus docetaxel therapy for lung cancer, will likely increase. It is probably safer to stop nintedanib or to switch to pirfenidone when ramucirumab plus docetaxel chemotherapy is initiated in order to lower the risk of gastrointestinal perforation. Continuing patients on nintedanib, as opposed to changing to ramucirumab, is probably safe and reasonable, although there has been no clinical trial to compare the efficacy of docetaxel plus nintedanib versus docetaxel plus ramucirumab. In addition, most importantly, gastrointestinal perforation should be considered in the differential diagnosis, when patients complain of abdominal pain during treatment with nintedanib and ramucirumab.
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